Hod et al. [86] described the anticancer properties of equol mediated via reduced expression of matrix metalloproteinases, which results in impaired metastasis characteristics in breast cancer cells and enhanced demethylation of BRCA1 and BRCA2 promoters, which reduce the risk of the early onset of breast cancer. Here, BRCA2 is linked to breast carcinoma.